2022
Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON
Wuyts W, Bonella F, Chaudhuri N, Varone F, Antin-Ozerkis D, Mueller H, Coeck C, Rohr K, Cottin V. Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON. 2022, 604. DOI: 10.1183/13993003.congress-2022.604.Peer-Reviewed Original ResearchContinued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON*
Bonella F, Wuyts W, Chaudhuri N, Varone F, Antin-Ozerkis D, Mueller H, Coeck C, Rohr K, Cottin V. Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON*. Pneumologie 2022, 76: s25-s26. DOI: 10.1055/s-0042-1747743.Peer-Reviewed Original Research
2021
Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON
Wuyts W, Bonella F, Chaudhuri N, Varone F, Antin-Ozerkis D, Mueller H, Coeck C, Rohr K, Cottin V. Continued nintedanib treatment in patients with progressive fibrosing ILDs: interim analysis of INBUILD-ON. 2021, pa2538. DOI: 10.1183/13993003.congress-2021.pa2538.Peer-Reviewed Original Research